Conjugation News and Research

RSS

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

8 Apr 2013

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Seahorse Bioscience launches XF Palmitate-BSA FAO Reagent for FAO assays

Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

27 Jun 2012

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

18 Jun 2012

Glucocorticoid steroids in intelligent medicine specifically hits relevant cells

Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data are based on rodent studies but if this principle is translated to humans it may greatly improve todays hazardous treatment with this type of potent steroids.

1 Jun 2012

Study reveals pathway that may help slow development of multiple myeloma

Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.

17 May 2012

Novo Nordisk granted exclusive rights to Caisson's heparosan-based drug delivery technology

Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, announced today that it has entered into a Development and License Agreement with Novo Nordisk A/S, a global healthcare company and leader in diabetes care.

From Novo Nordisk 2 May 2012

T-FET biosensor can detect biomolecules at ultra-low concentrations

A new quantum mechanical-based biosensor designed by a team at University of California, Santa Barbara offers tremendous potential for detecting biomolecules at ultra-low concentrations, from instant point-of-care disease diagnostics, to detection of trace substances for forensics and security.

17 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

PolyTherics announces acquisition of WEP

PolyTherics Limited, a provider of solutions to biopharmaceutical companies for the improvement of protein and peptide based drugs, is pleased to announce the acquisition of Warwick Effect Polymers, a provider of specialty biopolymers for the modification of biological products.

20 Jan 2012

Elevated ISG15 pathway may provide therapeutic targets for breast cancer

Interferon-stimulated gene 15 (ISG15), a ubiquitin like protein, is highly elevated in a variety of cancers including breast cancer. How the elevated ISG15 pathway contributes to tumorigenic phenotypes remains unclear and is the subject of a study published in the January 2012 issue of Experimental Biology and Medicine.

12 Jan 2012

State-of-the-art imaging system helps locate and count myriad connections between brain nerve cells

Researchers at the Stanford University School of Medicine, applying a state-of-the-art imaging system to brain-tissue samples from mice, have been able to quickly and accurately locate and count the myriad connections between nerve cells in unprecedented detail, as well as to capture and catalog those connections' surprising variety.

18 Nov 2010

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.

17 Nov 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Scientists and engineers from around the world will gather on the shores of Lake Ontario in Rochester, N.Y. next week to discuss some of the latest breakthroughs in lasers and optics and their applications to cutting-edge science, the development of new materials, and medicine.

21 Oct 2010

Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client. According to the agreement, Goodwin will develop the process to manufacture a unique therapeutic monoclonal antibody conjugate for diagnostic imaging purposes.

18 Oct 2010

Researchers find role of Vpr protein in HIV infection

Dr. Éric A. Cohen, Director of the Human Retrovirology research unit at the Institut de recherches cliniques de Montréal (IRCM), and his team published yesterday, in the online open-access journal PLos Pathogens, the results of their most recent research on the role of the Vpr protein in HIV (human immunodeficiency virus) infection and AIDS (acquired autoimmune deficiency syndrome).

3 Sep 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010